Nothing Special   »   [go: up one dir, main page]

IN2012DN02993A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02993A
IN2012DN02993A IN2993DEN2012A IN2012DN02993A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A IN 2993DEN2012 A IN2993DEN2012 A IN 2993DEN2012A IN 2012DN02993 A IN2012DN02993 A IN 2012DN02993A
Authority
IN
India
Prior art keywords
ebv
provides
present
cell
tcr
Prior art date
Application number
Inventor
Stauss Hans
Xue Shao-An
Topp Max
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of IN2012DN02993A publication Critical patent/IN2012DN02993A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/03Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05Epstein-Barr virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.
IN2993DEN2012 2009-09-29 2010-09-28 IN2012DN02993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (1)

Publication Number Publication Date
IN2012DN02993A true IN2012DN02993A (en) 2015-07-31

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993DEN2012 IN2012DN02993A (en) 2009-09-29 2010-09-28

Country Status (10)

Country Link
US (1) US8889141B2 (en)
EP (1) EP2483294B1 (en)
JP (2) JP6180114B2 (en)
KR (1) KR101760277B1 (en)
CN (1) CN102695717B (en)
AU (1) AU2010302477B2 (en)
ES (1) ES2584541T3 (en)
GB (1) GB0917090D0 (en)
IN (1) IN2012DN02993A (en)
WO (1) WO2011039508A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710810A (en) 2011-04-08 2016-09-30 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
EP3424947B1 (en) 2011-10-28 2020-11-25 Regeneron Pharmaceuticals, Inc. Genetically modified t cell receptor mice
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2014042226A1 (en) 2012-09-12 2014-03-20 株式会社癌免疫研究所 Antigen-specific helper t-cell receptor genes
AU2014290288B2 (en) 2013-07-15 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
DK3149031T3 (en) * 2014-05-29 2020-03-16 Us Health ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTORS
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
EP3212225A4 (en) 2014-10-31 2018-10-17 The Trustees of The University of Pennsylvania Methods and compositions for modified t cells
CN107001444B (en) * 2014-12-17 2020-11-27 中国科学院广州生物医药与健康研究院 T cell receptor for identifying EB virus short peptide
EP3237374A4 (en) 2014-12-23 2018-04-25 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
RS64540B1 (en) 2015-04-06 2023-09-29 Regeneron Pharma Humanized t cell mediated immune responses in non-human animals
CN104830793A (en) * 2015-05-05 2015-08-12 杨光华 DC cell based on LMP-1 antigen, targeting immune cell population, preparation method and applications thereof
SG10202110887PA (en) * 2015-06-09 2021-11-29 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
KR101794304B1 (en) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 EBV antigen specific T-cell receptor and use thereof
JP6999941B2 (en) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン Identification of immunogenic antigens from pathogens and their correlation with clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
CA3014515A1 (en) 2016-02-26 2017-08-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
TW201825499A (en) * 2016-09-19 2018-07-16 德商拜耳作物科學股份有限公司 Fused bicyclic heterocycle derivatives as pesticides
CN108218976B (en) * 2016-12-09 2021-11-05 香雪生命科学技术(广东)有限公司 Tumor antigen short peptide derived from LMP1
EP3666887A4 (en) 2017-08-10 2021-09-01 Good T Cells, Inc. Method for activating t cells for cancer treatment
SG11202101671PA (en) * 2018-11-27 2021-03-30 Univ Duke Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
CN113423724B (en) * 2018-12-27 2023-11-24 深圳华大生命科学研究院 EBV epitope high affinity T cell receptor
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (en) * 2021-10-14 2023-11-03 深圳大学总医院 T cell receptor and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (en) * 2007-11-09 2010-06-02 暨南大学 Recombination plasmid related with EB virus specificity TCR gene and method for constructing anti-EBV specific CTL

Also Published As

Publication number Publication date
CN102695717B (en) 2016-08-10
EP2483294B1 (en) 2016-07-13
US20120244132A1 (en) 2012-09-27
JP2016047064A (en) 2016-04-07
ES2584541T3 (en) 2016-09-28
EP2483294A2 (en) 2012-08-08
US8889141B2 (en) 2014-11-18
JP2013505734A (en) 2013-02-21
AU2010302477B2 (en) 2017-01-19
JP6180114B2 (en) 2017-08-16
AU2010302477A1 (en) 2012-04-19
KR20120074291A (en) 2012-07-05
WO2011039508A2 (en) 2011-04-07
GB0917090D0 (en) 2009-11-11
KR101760277B1 (en) 2017-07-21
WO2011039508A3 (en) 2011-06-30
CN102695717A (en) 2012-09-26

Similar Documents

Publication Publication Date Title
IN2012DN02993A (en)
MX350126B (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof.
PH12016500272A1 (en) T cell receptors
AU2017248122A1 (en) T cell receptors
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
MX2022005922A (en) Prame tcr receptors and uses thereof.
GB201206559D0 (en) Polypeptide
NZ598356A (en) Antigenic tau peptides and uses thereof
HRP20240676T1 (en) Fibronectin based scaffold domain proteins that bind to myostatin
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
NZ704192A (en) Cell-penetrating peptides and uses therof
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
JP2008543314A5 (en)
NZ706884A (en) Fc gamma receptor iib variants
MX2015003310A (en) Novel il-17a binding molecules and medical uses thereof.
JP2017514522A5 (en)
NZ705899A (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
WO2016130628A8 (en) Griffithsin mutants
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
MX2011007963A (en) Neil3 peptides and vaccines including the same.
MX2009007261A (en) Foxp3 peptide vaccine.
Koh et al. Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same